Cytek BiosciencesCTKB
About: Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Employees: 645
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
103% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 32
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
6% more funds holding
Funds holding: 128 [Q2] → 136 (+8) [Q3]
3% less capital invested
Capital invested by funds: $430M [Q2] → $415M (-$14.6M) [Q3]
1.7% less ownership
Funds ownership: 58.7% [Q2] → 57.01% (-1.7%) [Q3]
60% less call options, than puts
Call options by funds: $2K | Put options by funds: $5K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Piper Sandler David Westenberg 57% 1-year accuracy 12 / 21 met price target | 41%upside $8.50 | Overweight Maintained | 11 Nov 2024 |
Financial journalist opinion
Based on 3 articles about CTKB published over the past 30 days
